miraklide 10mg potahovaná tableta
vipharm s.a., ożarów mazowiecki array - 16590 escitalopram-oxalÁt - potahovaná tableta - 10mg - escitalopram
miraklide 20mg potahovaná tableta
vipharm s.a., ożarów mazowiecki array - 16590 escitalopram-oxalÁt - potahovaná tableta - 20mg - escitalopram
rapoxol 20mg enterosolventní tableta
sandoz s.r.o., praha array - 3681 sodnÁ sŮl rabeprazolu - enterosolventní tableta - 20mg - rabeprazol
sertralin vipharm 100mg potahovaná tableta
vipharm s.a., ożarów mazowiecki array - 13950 sertralin-hydrochlorid - potahovaná tableta - 100mg - sertralin
sertralin vipharm 50mg potahovaná tableta
vipharm s.a., ożarów mazowiecki array - 13950 sertralin-hydrochlorid - potahovaná tableta - 50mg - sertralin
setaloft 100mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 13950 sertralin-hydrochlorid - potahovaná tableta - 100mg - sertralin
setaloft 50mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 13950 sertralin-hydrochlorid - potahovaná tableta - 50mg - sertralin
zulbex 10mg enterosolventní tableta
krka, d.d., novo mesto, novo mesto array - 3681 sodnÁ sŮl rabeprazolu - enterosolventní tableta - 10mg - rabeprazol
zulbex 20mg enterosolventní tableta
krka, d.d., novo mesto, novo mesto array - 3681 sodnÁ sŮl rabeprazolu - enterosolventní tableta - 20mg - rabeprazol
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - cytostatika - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.